Cure8 research brief
This review addresses whether people with IBD face higher breast cancer risk and how treatments for one disease might affect the other—questions many patients and clinicians raise when cancer and IBD overlap.
Adult patients with IBD, especially those with a history of or concern about breast cancer; gastroenterologists and oncologists involved in coordinated care; researchers interested in microbiome and shared disease mechanisms.
This review looked at published studies up through May 2026 to compare epidemiology, biology, the microbiome, and treatment interactions between inflammatory bowel disease (IBD) and breast cancer. The pooled cohort evidence summarized by the authors did not find a clear overall increase in breast cancer risk for people with IBD.
The paper highlights shared biological pathways (inflammation, stromal changes, endocrine signaling) and emerging interests in microbiome links, but much of that work comes from separate models or different patient groups rather than studies that directly combine both diseases.
Clinically, the review focuses on treatment interactions: existing analyses have not shown a consistent rise in new or recurrent cancers among patients receiving common IBD therapies, but few studies specifically examine breast cancer.
The authors recommend individualized, coordinated care between gastroenterology and oncology when managing patients with both conditions.
The article is a narrative review (literature search through May 2026). Its conclusions emphasize that population-level breast cancer risk is not clearly increased in IBD and that treatment interactions need individualized assessment; it does not present new clinical trial data.
Review the original publication for the complete reporting, methods, and context.
Conflict statement: Declarations. Ethics approval and consent to participate: Not applicable. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests. Use of generative AI and AI-assisted technologies in the writing process: During preparation of the revised manuscript, the authors used ChatGPT solely for English-language polishing. The authors reviewed and edited the text and take full responsibility for the content of the manuscript.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
People with IBD commonly experience anxiety, depression, and other neurological symptoms. Understanding gut–brain axis mechanisms may help explain these comorbidities and point to future treatments.
PSC occurring with IBD changes cancer risk and surveillance needs: patients can have extensive but asymptomatic colitis and a higher colorectal and biliary cancer risk. The review outlines gaps in diagnosis, monitoring,...
Lung involvement is an underrecognized extraintestinal complication in IBD and can reflect disease activity, altered gut–lung immune signaling, or medication toxicity — distinguishing the cause is important for...
